BioSpace News Archive

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported financial results and business highlights for the third quarter 2019.

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that Management will present a company overview at the Stifel 2019 Healthcare Conference in New York, NY on Wednesday, November 20, 2019 at 9:10 a.m. ET.

Aridis Pharmaceuticals, Inc. reported financial and corporate results for the third quarter ended September 30, 2019.

Additional results from Phase 1 study of GDA-201 and new data on NAM technology platform to be presented at 61st Annual Meeting of the American Society of Hematology

Xencor, Inc. announced that company management will participate in two upcoming conferences

NanoString Technologies, Inc. announced that the company’s management is scheduled to present at the Stifel 2019 Healthcare Conference in New York City.

Altimmune, Inc., a clinical-stage biopharmaceutical company, announced financial results for the quarter ended September 30, 2019 and provided a business update.

DiaMedica Therapeutics Inc. provided a business update and reported its financial results for the three and nine months ended September 30, 2019.

Pipeline Therapeutics announced that the company will participate in the Stifel 2019 Healthcare Conference taking place November 19-21, 2019, in New York, NY.

The U.S. Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee voted 14 to 2 that the benefits of empagliflozin 2.5 mg do not outweigh the risks to support approval as an adjunct to insulin for adults with type 1 diabetes.